The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1324
ISSUE1324
November 2, 2009
Tadalafil (Adcirca) for Pulmonary Arterial Hypertension
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Tadalafil (Adcirca) for Pulmonary Arterial Hypertension
November 2, 2009 (Issue: 1324)
The FDA has approved use of tadalafil (Adcirca - Lilly/United Therapeutics) for treatment of pulmonary arterial hypertension (PAH).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.